DGRI Financial Services for the Medical Marijuana

Monaten, RSI och, und...?  

 

na alles gut?

du lagst leider schwer daneben mit deiner Ausage bei 0.0006

"Die wird weiter fallen. daran lasse ich mich messen"

Seit heute ist endlich update durch von otcmarkets.

die sind bald current und dann kann die reise beginnen.

 

Als der erste Trottel gesperrt war und nicht seinen quatsch hier rein gespamt hat.

Was is los Cancun? Hast dir das Prozentrechnen beibringen lassen? Hast du wenigstens einmal was nützliches zur aktuellen Situation zu sagen? Was sagst zur letzten news?

Wenn nicht freu ich mich das du dich zurück hältst...  

Marktgängig ?  

fillen und auch der SEC mitteilen.

transparenz.  nur dann steigt den ihr status  

warten hat sich gelohnt.  3 Fillings K8 raus und die Patent news

Nächste woche werden wir vom crowd funding hören  

gestern nur noch knapp 2 Mio im Ask auf der 13. Ich denke die sind heute recht bald Geschichte. Die 13 wurde richtig gut weggekauft.  

 

http://ireport.cnn.com/docs/DOC-1151867

 

an Broker wie  Aktionärsbank.de oder Saxobank wenden.

Diese werden weiterhin OTC werte handeln und auch DGRI.  

Marijuana: State-approved labs can't test private pot samples

By William Breathes Wed., May 14 2014 at 4:20 PM

State medical-marijuana testing labs licensed by the Marijuana Enforcement Division can no longer accept and test private samples dropped off by patients and caregivers. Legally, they're only allowed to test marijuana from state-licensed marijuana facilities.

Officials say the move keeps the state out of the federal government's cross-hairs by maintaining a tight lock on marijuana inventory. But it also punishes home-growing patients who want to know what they are putting in their bodies and prevents objective, third-party tests from being conducted on products currently for sale.
 

brauchen??


Why Marijuana Needs Chemical Quality Control Testing

http://www.popsci.com/article/science/...ical-quality-control-testing


Medical and otherwise

By
Francie Diep

Medical marijuana isn't always as advertised—at least not in the Seattle area, as one lab found out.

The lab, Analytical 360, recently worked with medical-marijuana patient Jessica Tonani to test samples from 22 area dispensaries and growers, The Seattle Times reports. The samples were all supposed to be of a strain of marijuana called Harlequin that has low levels of intoxicating chemicals, but high levels of therapeutic ones. Instead, five of the samples were the opposite. They were high in psychedelic tetrahydrocannabinol (THC), but had "virtually no" cannabidiol, which medical-marijuana users seek to help with the symptoms of epilepsy, inflammatory bowel disease and other diseases.

"You don't want a 6-year-old with epilepsy being put on a bus under the influence of a psychedelic chemical," Tonani told The Seattle Times. No, you do not.

As more states have legalized medical and recreational marijuana use, there's been growing interest in making sure pot products are clean and consistent and offer customers the effects they want. It’s just like any other commercial product, from ibuprofen to Greek yogurt. Last year, Chemical & Engineering News reported on small commercial labs, including Analytical 360, that had popped up to offer marijuana chemistry-testing services. "Why should medical marijuana be different from any other pharmaceutical?" C&EN asked, rhetorically. Before that, Slate published a story that included the reporter's brother, a scientist for a commercial lab who helps breeders and dispensaries determine the strength and quality—no mites or mold, please—of their stuff.

So the infrastructure for maintaining quality control in commercially sold marijuana is there. But the new Seattle Times report shows not every dispensary is testing its products, or heeding the results of tests. Consumer demand for more consistent products may push dispensaries to shape up. So might stricter laws. The Times points to the state government of Connecticut, which doesn't allow marijuana growers to give plants certain names, such as Harlequin, unless those plants meet certain chemical profiles.

What we don't recommend is relying on the goodwill of people who are in the business, despite what one grower told The Seattle Times:  

Medical-marijuana patients don’t always know what they’re getting

Testing shows that some marijuana strains are not what they purport to be in name, chemical content and genetics. This is particularly concerning for patients seeking pot low in intoxicants and high in pain-relief or other therapeutic qualities.



By Bob Young

Seattle Times staff reporter


Jessica Tonani, CEO of Verda Bio, a small Seattle biotech company, is researching the consistency and variety in medical-marijuana strains.

Jessica Tonani, CEO of Verda Bio, a small Seattle biotech company, is researching the consistency and variety in medical-marijuana strains.


Marijuana merchandise is ready for testing at Analytical 360, a lab that collaborated on research that showed inconsistencies.

A flower from a pot plant is enlarged under a microscope to check for adulterants, animals, mold, bugs and feces.
Enlarge this photo

Bugs are spotted on a computer screen when the marijuana flower under a microscope is blown up 230 times.

Jessica Tonani, a Seattle biotech executive, has what she calls a “broken stomach.” Put politely, she doesn’t digest food properly, which can cause vomiting, nausea and severe weight loss.

She’s had multiple surgeries, tried all the recommended treatments for her disorder and sits twice weekly for intravenous infusions.

Tonani, 38, decided several years ago to try pot. And it has worked for her, she said, especially strains low in the psychedelic chemical THC and high in the non-psychoactive ingredient cannabidiol, known as CBD.

As a medical-marijuana patient, Tonani knows it can be hard to find the rare strains that don’t make you high — and it can be even harder to get the same kind of pot consistently.

Testing shows that some marijuana strains are not what they purport to be in name, chemical content and genetics. This is particularly concerning for patients seeking pot low in intoxicants and high in pain-relief or other therapeutic qualities.

One strain widely known for its high-CBD and popular among medical-marijuana patients is called Harlequin. But when Tonani and a leading Seattle pot-testing lab analyzed 22 samples of Harlequin from various growers and dispensaries, five of them were high in THC and had virtually no CBD, which means people trying to take medicine were just getting high instead.

Misnaming and inconsistent chemical profiles are extremely common, said Dr. Michelle Sexton, a naturopath, founder of PhytaLAB and an adviser to the state Liquor Control Board.

This problem can be significant for patients who don’t want to be stoned while working or behind the wheel. It’s even more so for pediatric patients. “You don’t want a 6-year-old with epilepsy being put on a bus under the influence of a psychedelic chemical,” Tonani said.

And there’s this irony: Recreational-pot users will soon have greater assurances about the safety and chemical content of the pot they buy at retail stores in the state’s new legal pot system than the best-educated patients have in the largely unregulated medical system, where testing and accurate labeling are not mandated for dispensaries.

“It’s completely backwards from what it should be,” said Randy Oliver, chief scientist at Analytical 360, the lab that collaborated with Tonani’s firm on the research.

Alison Holcomb, chief author of Initiative 502, which legalized adult possession of marijuana, noted that I-502 is not — as many call it — a recreational-pot law. Its requirement that all products display THC and CBD content is likely to make medical patients more informed.

“It creates a legal marijuana market. The requirements apply equally to all marijuana that is being used, whatever the purpose of consumption,” said Holcomb, criminal-justice director for the ACLU of Washington state.

Dramatic differences

There’s still some mystery, due to a lack of scientific research, about how certain chemicals in pot impact different people.

But there’s enough evidence about the anticonvulsant qualities of CBD that the federal government’s only pot-growing facility plans to produce up to 600 kilos of high-CBD marijuana for study.

“The whole thing is just so loose and unregulated,” said Dr. Mahmoud ElSohly, director of the Marijuana Research Project at the University of Mississippi, about medical marijuana in states such as Washington. ElSohly’s goal is to grow high-CBD pot, with a very consistent chemical profile so it can be used in standardized research.

Since she’s been using pot, Tonani said, friends, family and other patients have queried her about what to use and where to get it. About a year ago, she said, she really came to understand dramatic differences in the quality of dispensaries and in marijuana called the same name.

That led her to form Verda Bio, a company devoted to researching the genetics and therapeutic uses of marijuana.

Tonani began collaborating with Analytical 360, which encourages transparency in the industry by posting on its website the results of all testing the lab has done on samples in the past 60 days.

She went out and bought five samples of Harlequin at Seattle-area dispensaries. Four of the samples varied considerably in their potency of THC and CBD. Even though they all had roughly a 2-to-1 ratio of CBD to THC, their variations in potency would make consistent dosing difficult. A fifth sample was radically different, with almost no CBD and high THC.

Tonani’s findings essentially matched an analysis by Analytical 360 of 17 samples called Harlequin it tested recently. Four of the samples were nothing like Harlequin.

Further DNA tests by Tonani on two of the samples she acquired showed that they were not even genetically similar.

Likely culprits

Experts cite a number of reasons for such inconsistencies.

One may be the lack of testing standards for labs analyzing medical marijuana, Sexton said. It’s a problem addressed by I-502 rules, which set requirements for accredited labs.

Another likely culprit is genetics. When growing from seeds — and not carefully cultivated clippings — there’s a possibility of variation in the plant’s chemical profile because of dominant and recessive genes, said breeder Chris Kelly, CEO of Seattle’s Green Lion Farms, and Seattle grower Jerry Whiting, co-owner of LeBlanc CNE, growers and brokers of medical marijuana.

Age also could be a factor, even when growing from clippings. The mother plants can lose their vigor over time, just as elderly people would.

Human error, such as the mislabeling of clippings, also could be to blame. Labels fall off and often get misplaced, Sexton said.

Lastly, growers and sellers could be engaging in fraud, calling something Harlequin because they think it will sell better or command a higher price.

Whiting believes the medical-marijuana community is too caring to engage in fraud. “No one is lying,” he said about the errantly named Harlequin samples.

Ross Skocilich is director of the Trees Collective in Seattle, where Tonani said she bought the outlier sample of Harlequin with virtually no CBD.

Skocilich said he got the Harlequin from a local grower who had not tested the pot. Skocilich had it tested and results were shared with anyone who asked for them. He still believes the marijuana was Harlequin, but grown from a seed with the kind of genetic variability that Kelly and Whiting described.

He said the collective’s budtenders likely would have advised patients looking for Harlequin that this particular batch did not fit the usual high-CBD profile.

Tonani described the collective as professional and said test results were provided when she asked for them. But she did not recall staff telling her the Harlequin did not contain CBD.

“We didn’t claim it did,” Skocilich said. “There was no hiding that it didn’t have high CBD.”

John Davis, CEO of two Seattle dispensaries and executive director of the Coalition for Cannabis Standards and Ethics, uses his own spot tests as a safeguard. “My policy is the grower tests it,” he said. “But I’ve done spot checks to see if someone is in the same ballpark.”

If Davis uncovers a problem, he said, he won’t work with that grower again. “It doesn’t pay to deal with those people at all,” Davis said. “I would encourage [dispensary owners] to at least be vigilant about things making claim to be high CBD.”

Connecticut developed standards

For consumers, one solution is to look at the chemistry, not just the names of marijuana, Tonani said.

As more become educated about CBDs, dispensaries will respond by displaying timely, accurate information, said Dr. Lara Taubner, chief scientist along with Oliver at Analytical 360.

The state also could develop standards for how much chemical variety should be allowed in a given strain, Sexton said, like Connecticut has done.

Growers in Connecticut can’t label pot products with the same name unless lab results show they vary less than 3 percent in their key chemicals.

Nor can growers use names that may encourage use for anything but a debilitating medical condition. Patients in Connecticut will not see pot with some names found in Washington dispensaries, such as “Durban Poison” and “AK-47.”

Connecticut’s rules are modeled on those for the pharmaceutical industry, said Bill Rubenstein, the state’s commissioner of consumer protection.

“The idea for patients is they’re getting a certain benefit not from pot in general but from the active ingredient profile,” Rubenstein said. “They should have a degree of assurance that the product that works for them is the same product they are going to purchase each time.”

All of this moves medical marijuana closer to Big Pharma, which is anathema for many growers, patients and merchants.

But such standards are common among agricultural crops such as Red Delicious apples, Oliver said, so why not have the similar requirements for Harlequin and other strains?

“I’d argue patients are overwhelmed with the condition they have and it’s difficult knowing what to look for and how to get what you need. We need to simplify things for patients,” Tonani said.  

ist dir immer noch nicht langweilig geworden??? wer will abladen??  DGRI die nicht Diluten??

Oh man ja DGRI hat etwas Zeit gebraucht um Dutch Mining, LLC in Chapter 7 zu schicken.

- Aber jetzt kommen Hammer NEWS ,

- OTCmarkets.com wurde nach 2 Jahren upgedatet

und ist immer noch alles negativ?? sorry aber für mich ist das lächerlich weiterhin zu behaupten das die nix machen, bzw. wofür der ganze Aufwand? denk mal nach.

 

in paar Tage kommt q10 bzw. DGRI wird Current

O nein , doch nicht Current

lächerlich einfach nur lächerlich
 

weiter hin die ganzen Hammer Fakten zu ignorieren  

 

TLANTA, GA July 15, 2014-- Dutch Gold Resources, Inc. (DGRI.OTC) (the “Company”) (dutchgoldinc.com) today announced that it has formed a subsidiary, Ascendant Beverages, Inc. (ABI), to produce hemp flavored teas, with and without Cannabidiols (CBD), and bottled waters. The Company has secured the rights to the flavoring/ingredient profiles of over a dozen beverages and will begin manufacturing product during August of 2014.

CBD-infused water will have all the advantages of traditional pure spring water plus the added health and wellness benefits of CBD. The beverages will be marketed throughout similar distribution channels as bottled drinking water at retail and grocery outlets, and will leverage the MMJ distribution network that is building for its’ Potency Testing Kit.
CBD has shown positive as described in the United States Health Department Patent # 6,630,507 results with Parkinson's disease, HIV, Down's Syndrome, Crohn's disease, Rheumatoid Arthritis, Diabetes, Post Heart Operation and Heart patients, including high blood pressure, Alzheimer's and many other conditions. CBD has been shown to be a natural T-cell enhancer. For further information on CBD see http://en.wikipedia.org/wiki/Cannabidiol.
In 2010, sales of tea and ready-to-drink (RTD) tea increased 5.1 percent, reaching $4.3 billion in food, drug, convenience stores and mass merchandisers, excluding Walmart, according to Mintel’s July 2011 “Tea and RTD Teas – U.S.” report. Canned and bottled tea as well as refrigerated RTD tea drove growth in the category, the Chicago-based market research firm reported. According to www.BottledWater.org, sales of bottled waters exceeded $11 billion for the same period.
The formation of Ascendant Beverages, Inc. signals the Company’s intention to build an additional revenue line that can be grown organically, where the Company has also identified multiple opportunities for expansion through acquisition. “As we have looked at business plans for companies that are seeking growth capital, we continue to find business niches inside the MMJ sector that are potentially positioned for significant growth. We think the beverage sector demographics are quite favorable. Further, the data on CBD continues to generate interest from both established marketers and the scientific community,” said Daniel Hollis, CEO of Dutch Gold Resources, Inc.  

Dutch Gold Executes License Agreement with Abba Medix Corporation

http://finance.yahoo.com/news/...tes-license-agreement-110000130.html  

http://ih.advfn.com/p.php?pid=nmona&article=62984860  

hier die nächste News :)))

So in Richtung stock-Dividende ... o.a. Märchen  

hohes Volumen heute wieder...
Da machen wohl noch die Kasse, die nen kleinen Gewinn haben. Rette sich wer kann.  

wird's blutig. Und die Experten hier haben längst das weite gesucht....
Untergetaucht und wollen den Thread am liebsten verschwinden lassen.  

bin immer noch da , und stehe zu meinem Invest

und auch klar das der letzter Trade jetzt in minus ist! sind zwar Freebees aber wie gesagt in minus.

Klar wenn Werte nicht laufen verkaufen ich die auch mit minus , kassiere steuern zurück und zocker wo anders. Nur bei DG bleibe ich weiterhin dabei.

In einem Posting hab ich geschrieben was passieren musst , damit DGRI steigt